Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2015

Calles Antonio, Sholl Lynette M, Rodig Scott J, Pelton Ashley K, Hornick Jason L, Butaney Mohit, Lydon Christine, Dahlberg Suzanne E, Oxnard Geoffrey R, Jackman David M, Jänne Pasi A

Abstract excerpt

PURPOSE: LKB1 loss is common in lung cancer, but no assay exists to efficiently evaluate the presence or absence of LKB1. We validated an IHC assay for LKB1 loss and determined the impact of LKB1 loss in KRAS-mutant non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: We optimized and validated an IHC assay for LKB1 (clone Ley37D/G6) using a panel of lung cancer cell lines and tumors with known LKB1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to AMP-Activated Protein Kinase Kinases

Share to Carcinoma, Non-Small-Cell Lung

Share to Kaplan-Meier Estimate

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 25737507
DOI: 10.1158/1078-0432.CCR-14-3112

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.PMID 25737507Read ↗

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.Semantic proximity Read ↗

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.Semantic proximity Read ↗

Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Semantic proximity Read ↗

Prevalence and specificity of LKB1 genetic alterations in lung cancers.Semantic proximity Read ↗

LKB1 gene mutations in Japanese lung cancer patients.Semantic proximity Read ↗

Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.Semantic proximity Read ↗

Loss of FGL1 induces epithelial‑mesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinomaSemantic proximity Read ↗

Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers.Semantic proximity Read ↗

Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas.Semantic proximity Read ↗

Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.Semantic proximity Read ↗

Clinicopathologic correlations of liver kinase B1, E-cadherin, and N-cadherin expression in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.